Showing results (281-290 of 419) with videos related to

Sort By:
Pageof 42
RMD Open|August 13, 2021
Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3Daniel Aletaha, René Westhovens, Cecile Gaujoux-Viala, et al.
Annals of the Rheumatic Diseases|November 6, 2021
Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 yearsKevin L Winthrop, Yoshiya Tanaka, Tsutomu Takeuchi, et al.
Annals of the Rheumatic Diseases|June 10, 2015
Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)Gerd R Burmester, Andrea Rubbert-Roth, Alain Cantagrel, et al.
Arthritis and Rheumatism|February 7, 2003
Identification and characterization of SmD183-119-reactive T cells that provide T cell help for pathogenic anti-double-stranded DNA antibodiesGabriela Riemekasten, Dirk Langnickel, Fanny M Ebling, et al.
Rheumatology and Therapy|July 31, 2026
Filgotinib in Moderate to Severe Rheumatoid Arthritis in a Real-World Setting: Up to 6-Month Effectiveness, Patient-Reported Outcomes, and Persistence, and up to 24-Month Safety from More than 1400 Patients in the FILOSOPHY and PARROTFISH StudiesGerd R Burmester, James Galloway, Karen Bevers, et al.
Annals of the Rheumatic Diseases|October 29, 2020
Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programmeStanley B Cohen, Ronald F van Vollenhoven, Kevin L Winthrop, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 24, 2017
A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid ArthritisMichael E Weinblatt, Iain B McInnes, Joel M Kremer, et al.
Annals of the Rheumatic Diseases|August 2, 2013
A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)Gerd R Burmester, Andrea Rubbert-Roth, Alain Cantagrel, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 29, 2020
Association of High Serum Interleukin-6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc AnalysisAnita Boyapati, Sergio Schwartzman, Jérôme Msihid, et al.
Rheumatology (Oxford, England)|August 14, 2015
Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritisGerd R Burmester, Patrick Durez, Galina Shestakova, et al.
Pageof 42